Podcasts about Acute coronary syndrome

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome.Morphine's use in the Acute Coronary Syndrome (ACS) algorithm.Why Morphine is helpful for patients with ACS.Contraindications and considerations for the safe administration of Morphine.Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors.Common dosing & administration of Morphine.Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration.Possible side effects of Morphine administration.Narcan as an antidote to Morphine if needed.Good luck with your ACLS class!Links: Buy Me a Coffee at https://buymeacoffee.com/paultaylor Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/Free Prescription Discount Card - Download your free drug discount card to save money on prescription medications for you and your pets: https://safemeds.vipPass ACLS Web Site - Episode archives & other ACLS-related podcasts: https://passacls.com@Pass-ACLS-Podcast on LinkedIn

Send us a textToday we're introducing a new format—the first episode in our Clinical Practice Guidelines series. This week, Drs. Mike and John Fralick discuss the 2025 ACC/AHA Clinical Practice Guidelines for Acute Coronary Syndrome. Here we go! Support the show

Send us a textWelcome back Rounds Table Listeners! Today we're introducing a new format—the first episode in our Clinical Practice Guidelines series. This week, Drs. Mike and John Fralick discuss the 2025 ACC/AHA Clinical Practice Guidelines for Acute Coronary Syndrome. Here we go!2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients With Acute Coronary Syndromes (0:00 - 18:56)Mike's interview with Dr. Jeff Carson:Episode 110 - Restrictive versus Liberal Transfusion in Myocardial Infarction with Dr. Jeff CarsonThe Good Stuff:Egg cracking tips! (18:57 - 19:47)Jerro (19:48 - 20:47)Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances, discusses a recently published original research paper on Apixaban Dose in Patients With Atrial Fibrillation and Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention: Insights From AUGUSTUS.

Mirza Umair Khalid, MD, social media editor of JACC: Cardiovascular Interventions, and William F. Fearon, MD, FACC, discuss analysis from FAME III trial comparing outcomes of CABG vs FFR-guided multivessel PCI for patients in ACS versus CCS.

Justin Coleman speaks with Kate Ziser, a pharmacist at the Princess Alexandra Hospital in Brisbane, about her paper on the role of triple antithrombotic therapy in patients with atrial fibrillation following coronary stent insertion. Kate explains when triple therapy is indicated, the duration of therapy, and the step-down approach to antithrombotic therapy. Read the full article by Kate and her co-authors in Australian Prescriber.

Antithrombotic Therapy in ACS

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting. Donations at Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated and will help ensure others can benefit from these tips as well.Good luck with your ACLS class!Helpful Listener Links:Practice ECG rhythms at Dialed Medics - https://dialedmedics.com/

This episode of JACC-Baran features a brief discussion on Kendrick Lamar and the history of racial discrimination in the United States. Then Hiroki Ueyama, MD, from Emory University discusses his study on P2Y12 inhibitor pre-treatment in NST-ACS using data from the Chest Pain-MI Registry. The study examines how guideline changes have influenced clinical practice, revealing a decline in pre-treatment rates, significant practice variations, and no major differences in outcomes except for longer hospital stays in CABG patients. Watch the video or listen as a podcast here, then check out the JACC article: https://www.jacc.org/doi/10.1016/j.jacc.2024.09.1227

Acute Coronary Syndrome (ACS) remains a leading cause of morbidity and mortality worldwide, demanding a nuanced approach to diagnosis, risk stratification, and management. In this episode of MedPOD AFMC, host Brig (Dr) J Muthukrishnan is joined by Lt Col (Dr) Ankush Gupta, an eminent cardiologist from the Army Institute of Cardio-Thoracic Sciences, to discuss the evolving landscape of ACS care.From recognizing different clinical presentations to utilizing high-sensitivity biomarkers and risk scores, this conversation delves into the latest advancements in ACS assessment. The discussion also explores modern treatment strategies. With an evidence-based approach and real-world insights, this episode provides a comprehensive understanding of ACS, making it an essential listen for physicians, medical students, and healthcare professionals involved in acute cardiac care.

Broken heart syndrome, which is left ventricular dysfunction in the absence of coronary artery disease, is so-called because it can be triggered by extreme stress, such as loss of a loved one. Stress can also, in people with existing disease, trigger an acute coronary event and exacerbate arrhythmias.In this episode, the MIMS Learning editors Dawn Liz Powell and Rhiannon Ashman review how stress — both in the short and long term — can affect the heart. They look at broken heart syndrome (also known as takotsubo syndrome) and how stress can lead to an unhealthy lifestyle and, consequently, is a risk factor for cardiovascular disease.The editors also discuss how GPs and other primary care health professionals can support patients who are chronically stressed both by helping them to manage their stress levels and by addressing the risk factors that can develop as a consequence, directly or indirectly, of stress.You can access the website version of this podcast on MIMS Learning to make notes for your appraisal. MIMS Learning offers hundreds of hours of CPD for healthcare professionals, along with a handy CPD organiser.Please note: this podcast is presented by medical editors and discusses educational content written or presented by doctors, nurses and other healthcare professionals on the MIMS Learning website and at live events.Further learning on MIMS LearningAchieving new cholesterol targets in primary careCoronary artery disease in womenGuidance update: latest NICE guidelines on cardiovascular disease risk assessment and reductionGuidance update: latest NICE guidelines on type 2 diabetes in adultsGuidance update: NICE guidelines on hypertensionObesity in adultsPodcast: Professor Alex Miras on supporting people with obesityPodcast: NASP's Monica Boulton on making best use of social prescribing in primary careResources for supporting people to improve their mental wellbeingTakotsubo syndrome: clinical reviewWellbeing masterclass Hosted on Acast. See acast.com/privacy for more information.

In this podcast, Dr. Valentin Fuster discusses a study on the use of P2Y12 inhibitor pretreatment in patients with non-ST elevation acute coronary syndrome, revealing significant variability in its application across institutions and operators. Despite initial hypotheses of benefit, the findings indicate no significant difference in patient outcomes, suggesting that routine pretreatment may not be necessary, especially when treatment is initiated within 24 hours of symptom onset.

Join us as Monee and Meredith with the rest of the hospital medicine team reflect on the past year, discussing some favorite insights gained covering a range of topics, including diabetic foot infections, sepsis, sickle cell inpatient management, syncope, psychiatry for the hospitalist, and acute coronary syndrome.  No CME for this episode, but claim CME for past shows at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Introduction Picks of the Year Diabetic Foot Infections  Sepsis Sickle Cell Inpatient Management  Psychiatry Primer Syncope  Acute Coronary Syndrome  Reflections from the Year  Credits Written, Produced, and hosted by: Meredith Trubitt  MD; Monee Amin MD Script Written: Caroline Coleman, MD, RJ Blackburn, MD Cover Art: Caroline Coleman, MD Reviewer: Rahul Ganatra MD Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Sponsor: Rosetta Stone Redeem your 50% off at rosettastone.com/curbsiders

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting so that others can benefit from these ACLS tips as well. Donations via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Good luck with your ACLS class!

Maddy, Youssef and Andrew share their approach to acute coronary syndrome as they discuss a case presented by Sharmin. Acute Coronary Syndrome Framework To join us live on Virtual Morning Report (VMR), sign up HERE. Download CPSolvers App here RLRCPSOLVERS

JACC Associate Editor Seng Chan You, MD, and author Hiroki Ueyama, MD discuss this study presented at AHA and published in JACC. NCDR study finds a steady decline in P2Y12 inhibitor pretreatment for NSTE-ACS in the US, but significant variability persists among operators, institutions, and regions. This practice was not associated with any benefits but was linked to a longer length of stay among those undergoing CABG, underscoring the importance of maintaining efforts to integrate evidence into clinical practice.

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@Pass-ACLS-Podcast on LinkedInGive Back & Help Others: Your support helps cover the monthly cost of software and podcast & website hosting so that others can benefit from these ACLS tips as well. Donations made via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Make a difference in the fight against breast cancer by donating to my Men Wear Pink fundraiser for the American Cancer Society (ACS) at http://main.acsevents.org/goto/paultaylor Every dollar helps in the battle with breast cancer.Good luck with your ACLS class!

Darshan H. Brahmbhatt, Podcast Editor of JACC: Advances discusses a recently published original research paper on machine-learning for phenotyping and prognostication of myocardial infarction and injury in suspected acute coronary syndrome.

Quit playing games with my heart Yet another beat no to skip here with part 2 of our conversation with cardiologist Dr. Sanjeev Francis (@, Maine Medical Center)for acute coronary syndrome. Learn about the warranty on stress tests, initial management of ACS and how to deal with those pesky elevated troponins from patients with sepsis. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Start Part 1 Intro Rapid fire questions/Picks of the Week Case 1 History and Physical ECGs  Definitions Risk Stratification Tools Non-invasive Testing Options End Part 1 Start Part 2 Case 2 Warranty on Non-invasive Testing Invasive Management of non ST elevation ACS  Medical Management of non ST elevation ACS  Case 3 Myocardial Injury Definitions Diagnostics to Consider for Myocardial Injury Transitions of Care Outro End Part 2 Credits Producer, Writer, Show Notes, Hosts: Meredith Trubitt, MD, MPH, Monee Amin MD Infographic, Cover Art: Caroline Coleman, MD Reviewer: Rahul Ganatra, MD, MPH Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Sanjeev Francis, MD Sponsor: Babbel Get up to 60% off your Babbel subscription - but only for our listeners at Babbel.com/CURB. Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off their first month. Sponsor: Panacea Financial  If you're ready to join the thousands of doctors who have declared independence from traditional banks, visit panaceafinancial.com today.

In the September 10, 2024, issue of JACC, the study by Dr. Doron Seeker and colleagues investigates alirocumab's impact on cardiovascular outcomes related to triglyceride levels. Despite effectively lowering LDL cholesterol, alirocumab did not show significant clinical benefit through triglyceride reduction, suggesting that its efficacy may be limited in addressing cardiovascular risk associated with elevated triglycerides.

Don't skip a beat and join us  in part 1 of our conversation with cardiologist  Dr. Sanjeev Francis (@, Maine Medical Center)for acute coronary syndrome. First up, the basics on physical exam, how to interpret high-sensitivity troponin and how to think through the spectrum of acute coronary syndrome. Claim CME for this episode at curbsiders.vcuhealth.org! Patreon | Episodes | Subscribe | Spotify | YouTube | Newsletter | Contact | Swag! | CME Show Segments Start Part 1 Intro Rapid fire questions/Picks of the Week Case 1 History and Physical ECGs  Definitions Risk Stratification Tools Non-invasive Testing Options End Part 1 Start Part 2 Case 2 Warranty on Non-invasive Testing Invasive Management of non ST elevation ACS  Medical Management of non ST elevation ACS  Case 3 Myocardial Injury Definitions Diagnostics to Consider for Myocardial Injury Transitions of Care Outro End Part 2 Credits Producer, Writer, Show Notes, Hosts: Meredith Trubitt, MD, MPH, Monee Amin MD Infographic, Cover Art: Caroline Coleman, MD Reviewer: Rahul Ganatra, MD, MPH Showrunners: Matthew Watto MD, FACP; Paul Williams MD, FACP Technical Production: PodPaste Guest: Sanjeev Francis, MD Sponsor: Mint Mobile  To get your new 3-month premium wireless plan for just 15 bucks a month, go to mintmobile.com/CURB.  Sponsor: Freed You can try Freed for free right now by going to freed.ai. And listeners of Curbsiders can use code CURB50 for $50 off your first month.  Sponsor: American College of Physicians Preorder ACP MKSAP to receive discounted pricing plus free MKSAP 19 premium content you can use now at acponline.org/acpmksap

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore the pathophysiology and novel therapeutic strategies to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Moving beyond lipid lowering to address residual inflammatory riskNovel anti-inflammatory targets for ASCVD To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clipsClinicalThought commentariesPodcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they explore new and emerging strategies to target residual risk associated with systemic inflammation in patients with ASCVD and CKD.    Episode outline:   The relationship among systemic inflammation, ASCVD, and CKD The role of cardiologists and nephrologists in screening and mitigating systemic inflammation To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD Podcast episode 3, featuring faculty discussion of new and emerging therapies to target inflammatory risk in patients with ASCVD and CKD 

In this CCO Nephrology podcast episode, hear from cardiologist Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC, and nephrologist Mark J. Sarnak, MD, MS, as they discuss new and emerging therapies designed to target residual inflammatory risk associated with ASCVD and CKD.    Episode outline:   Colchicine: inhibition of NLRP3 inflammasome assembly/activationCanakinumab (anti–IL-1β monoclonal antibody)Ziltivekimab (anti–IL-6 monoclonal antibody)Other emerging targets/therapies To learn more about targeting residual risk associated with systemic inflammation, find more educational activities and resources with the links below:   CME-certified text module with animated pathophysiology video and faculty voice audio clips ClinicalThought commentaries Podcast episode 1, discussing residual risk associated with systemic inflammation and the role of cardiologists and nephrologists in mitigating risk in ASCVD and CKD Podcast episode 2, discussing novel therapeutic approaches to address residual inflammatory risks in patients with ASCVD and CKD 

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@PassACLS on X (formally known as Twitter)@Pass-ACLS-Podcast on LinkedInGive back & help others. Your support will help cover the monthly cost of software and podcast & website hosting. Donations made via Buy Me a Coffee at https://buymeacoffee.com/paultaylor are appreciated.Good luck with your ACLS class!

Get full access to Cardiology Trial's Substack at cardiologytrials.substack.com/subscribe

Commentary by Dr. Valentin Fuster

Acute Assessment Of Patients With High Cardiovascular Risk Post-acute Coronary Syndrome (TELE-ACS)

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@PassACLS on X (formally known as Twitter)@Pass-ACLS-Podcast on LinkedInGive back - buy Paul a bubble tea hereGood luck with your ACLS class!

Ticagrelor Monotherapy in Patients with Acute Coronary Syndrome: An Individual Patient Data Meta-Analysis of Randomized TICO and T-PASS Trials

Note to readers: Since going live with Cardiology Trials Substack in January of 2024 we have been exclusively covering trials that we have categorized as belonging to the major subject heading “Acute Coronary Syndrome” belonging to the subsection “Medicines”. Our indexing scheme was described in one of our original posts and we encourage our audience to read it if you have not already. This is pertinent because the next several trials being presented may seem to come out of the blue but we assure you there is a method.N Engl J Med 2007;357:2011-15.Background Up to now we have presented trials involving major foundational medical therapies for acute coronary syndrome which include aspirin, thrombolytic agents and anticoagulation, but not those involving percutaneous coronary intervention (PCI) as they are reserved for another section. But, by the turn of the 21st century, PCI had become the dominant up-front strategy for revascularization in many countries around the world. Clinical trials demonstrated it improved outcomes, the main one being re-infarction, compared to thrombolysis in patients with STEMIs, and there was an evolving evidence for it in non-ST-segment elevation acute coronary syndrome (STEACS) as well, where thrombolysis had not demonstrated any significant benefits.As PCI became dominant, antithrombotic strategies for optimizing outcomes following PCI evolved along with it. These early trials generally involved a mixture of patient phenotypes (acute vs elective PCI) and were relatively small and of limited quality by comparison to many of the seminal trials presented thus far. Instead of presenting each of these smaller studies, we direct readers to a narrative review that nicely describes the evolution of dual-antiplatelet therapy for PCI and other indications.Briefly: dual-antiplatelet therapy with aspirin and ticlopidine, an antiplatelet agent belonging to the drug class of thienopyridines, which inhibits platelet aggregation induced by ADP, was found superior to aspirin alone or aspirin plus anticoagulation when PCI was performed; however, there were concerns about its safety. Clopidogrel was developed after ticlopidine; it had a similar mechanism of action but less safety concerns and could be given as a loading dose to produce more rapid effects. Despite limited evidence from clinical trials comparing it head-to-head with ticlopidine it became the dominant thienopyridine agent on the market and still has a prominent role in the management of cardiovascular diseases today.Following PCI and dual-antiplatelet therapy with aspirin and clopidogrel, patients continue to have an elevated risk of coronary events, in general, and in-stent related coronary events, in particular. Some of this risk has been attributed to limitations of clopidogrel itself. Clopidogrel has modest antiplatelet effects (compared to other thienopyridines) with substantial interpatient variability due to genetic polymorphisms that impact clopidogrel metabolism and antiplatelet efficacy. Clopidogrel also has a delayed onset of action, which is especially relevant regarding its ability to protect against the dreaded adverse event of early in-stent thrombosis.Prasugrel is a thienopyridine—developed after clopidogrel—that inhibits platelet aggregation more rapidly, consistently and to a greater extent. The Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel–Thrombolysis in Myocardial Infarction (TRITON–TIMI) 38 trial sought to test the hypothesis that prasugrel would reduce major cardiovascular events compared to clopidogrel in patients with acute coronary syndrome undergoing PCI.Cardiology Trial's Substack is a reader-supported publication. To receive new posts and support our work, consider becoming a free or paid subscriber.Patients Eligible patients had either moderate-to-high risk unstable angina (UA) or NSTEMI or STEMI. UA and NSTEMI were defined by ischemic symptoms lasting 10 minutes or more and occurring within 72 hours before randomization, a TIMI risk score of 3 or more, and either ST-segment deviation of 1 mm or more or elevated levels of a cardiac biomarker of necrosis. STEMI was traditionally defined. Key exclusion criteria included an increased risk of bleeding, anemia, thrombocytopenia, a history of pathologic intracranial findings, or the use of any thienopyridine within 5 days before enrollment.Baseline characteristics The median age of patients was 61 years with 13% being ≥75 years and 74% were men; over 90% were white. The index event was UA or NSTEMI in 74% and STEMI in 26%.  PCI was performed in 99% of patients and split evenly between those receiving bare metal or drug eluting stent(s).  18% of patients had a prior MI, 23% had diabetes, 64% had hypertension and 38% were tobacco users. Only 11% of patients had CKD defined as a creatinine clearance ≤60 ml/min.Procedures A loading dose of prasugrel 60 mg or clopidogrel 300 mg was given in a double blind manner anytime between randomization up to 1 hour after leaving the catheterization laboratory. In order to be randomized, the plan for PCI had to be known. This could occur before going to the cath lab for planned PCI, if the anatomy was already known or occur in the cath lab during the case where anatomy was determined and PCI was performed. If PCI was planned, patients were eligible to undergo pretreatment with the study drug for up to 24 hours prior to PCI.Treating physicians determined the vessels treated, devices used, and adjunctive medication administered to support PCI. After PCI, patients received maintenance doses of either prasugrel 10 mg daily or clopidogrel 75 mg daily. Use of aspirin at a dose of 75 to 162 mg daily was recommended. Study visits were conducted at hospital discharge, 30 days, 90 days, and 3-month intervals thereafter, for a total of 6 to 15 months.Endpoints The primary efficacy endpoint was a composite of cardiovascular death, nonfatal MI or stroke during the follow up period. A prespecified “landmark” analysis was undertaken to compare the primary endpoint event rate up to 3 days following randomization and from day 3 to the end of the study. The sample size calculation was event-driven and it was determined that 875 primary endpoint events would provide 90% power to detect a relative risk reduction of 20%. A prespecified analysis performed after 650 events revealed a lower than anticipated event rate and the investigators increased the sample size accordingly.Results A total of 13,608 patients (10,074 with UA or NSTEMI and 3534 with STEMI), from 707 sites in 30 countries were enrolled. There were 6,813 patients assigned to the prasugrel group and 6,795 assigned to clopidogrel. The median duration of therapy was 14.5 months. Prasugrel significantly reduced the primary composite endpoint compared to clopidogrel (9.9% vs 12.1%; HR 0.81; 95% CI 0.73-0.90; P

Pre-Hospital Rule-Out of Non-ST-Segment Elevation Acute Coronary Syndrome by a Single Troponin Measurement: Final One-Year Outcomes of the ARTICA Randomised Trial (AHA 2023)

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed. Connect with me:Website: https://passacls.com@PassACLS on X (formally known as Twitter)@Pass-ACLS-Podcast on LinkedInGive back via PayPal Good luck with your ACLS class!

Looking for more information on this topic? Check out the Drugs to Treat Acute Coronary Syndrome brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Twitter: https://twitter.com/mesage_hub Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including over 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.

Commentary by Dr. Candice Silversides

With the expertise of top cardiologists and medical researchers Dr. Michael Koren and Dr. Miciah Jones we follow up on the October 18, 2023 podcast Exploring Cardiac Health: Acute Coronary Syndrome, Gender Differences, and Cholesterol Management Ep 148. We uncover the truth about Plavix and its role in treating, not preventing, heart disease. We also shed light on the overlooked signs of heart disease in women and how the medical community is stepping up its game in diagnosis. Dive into hospital procedures for heart attack assessment and the potential lifelong use of cholesterol drugs.Ever wondered about the complexities of stress testing in heart disease diagnosis? We unravel these intricacies, discuss the pros and cons of various tests, and emphasize the importance of collaborating with the right healthcare professionals. Highlighting how a deep understanding of your body's anatomy and physiology can help detect potential health issues, we walk you through the labyrinth of diagnostic options. Don't miss out on this enlightening and potentially life-saving discussion as we delve into heart disease and its management.Be a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedIn Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

Are you prepared for a journey into the fascinating world of cardiac health? We promise you insights that could be life-altering. Dr. Michael Koren and Dr. Miciah Jones illuminate us on acute coronary syndrome and the immediate benefits of high-dose statin medication. Their expertise in diet, exercise, prevention, and procedural therapy provides a holistic perspective on coronary artery disease. We then channel our focus to the often-overlooked topic of gender differences in heart disease. With women presenting more vague symptoms and experiencing higher complications when treated for a STEMI, it's a conversation that is crucial now more than ever. Join us as we traverse this critical landscape, exploring the alarming trend of plateauing progress in reducing cardiovascular deaths in the United States. It's an engaging discourse that serves as a call to action for us all to work towards reducing deaths from heart disease.As we wrap up this episode, we demystify the complexities of cholesterol. Shedding light on the contrasting roles of LDL and HDL cholesterol. The significance of managing cholesterol levels, and we talk about how physical activity and statins are allies in this fight. Our segment on the potential side effects of statins and ways to minimize the residual risk of cardiovascular disease is not to be missed. So, tune in! We guarantee you'll walk away with a wealth of knowledge and practical tips for a heart-healthy lifestyle.Rebroadcast from September 6, 2023, WJCT Sip & Science eventBe a part of advancing science by participating in clinical researchShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramTwitterLinkedIn Powered by ENCORE Research GroupMusic: Storyblocks - Corporate InspiredThank you for listening!

Dear folks, as you know ESC 2023 acute coronary syndrome guideline has many new concepts, we decided to summarize its content and we hope you will enjoy listening to this episode. You can also download the slide set prepared by ESC by clicking the following link:http://ecardiocast.com/wp-content/uploads/2023/10/ACS-Guideline.pdf

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.**American Cancer Society (ACS) Fundraiser This is the fifth year that I'm participating in Men Wear Pink to increase breast cancer awareness and raise money for the American Cancer Society's life-saving mission.I hope you'll consider contributing.Every donation makes a difference in the fight against breast cancer! Paul Taylor's ACS FundraiserTHANK YOU! Connect with me:Website: https://passacls.com@PassACLS on Twitter@Pass-ACLS-Podcast on LinkedInGive back & support the show:via PayPal Good luck with your ACLS class!

Elite Athletes and COVID-19; Statin and Ezetimibe in Acute Coronary Syndrome; Redo-TAVR; Chagas Disease Progression

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@PassACLS on Twitter@Pass-ACLS-Podcast on LinkedInGive back & support the show:via PayPal Good luck with your ACLS class!

Acute Coronary Syndrome and Acute Chest Pain

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS. Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine. Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors. Common dosing & administration of Morphine. Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed. Connect with me:Website: https://passacls.com@PassACLS on Twitter@Pass-ACLS-Podcast on LinkedInGive back & support the show:via PayPal Good luck with your ACLS class!

In this episode of Curbside Consults, we examine the 2022 scientific statement from the American Heart Association on the management of acute coronary syndrome in the older adult population. We are joined by Dr. Abdulla Damluji, the lead author on the scientific statement. Dr. Damluji is an interventional cardiologist at Inova Heart and Vascular Institute and Associate Professor of Medicine at Johns Hopkins University School of Medicine.

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome or ACS.Morphine's use in the Acute Coronary Syndrome (ACS) algorithm. Why Morphine is helpful for patients with ACS. Contraindications and considerations for the safe administration of Morphine.Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors.Common dosing & administration of Morphine.Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration.Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@PassACLS on Twitter@Pass-ACLS-Podcast on LinkedInGive back & support the show:via PayPal Good luck with your ACLS class!

This episode covers acute coronary syndrome.Written notes can be found at https://zerotofinals.com/medicine/cardiology/acs/ or in the cardiology section of the 2nd edition of the Zero to Finals medicine book.The audio in the episode was expertly edited by Harry Watchman.

In this week's episode of the #CodaPodcast, Gemma Figtree – a Cardiologist and Professor discusses the profound inequality of gender issues.

While still new, emergency medicine pharmacists and pharmacotherapy has not had its own platform to present the latest evidence and issues facing emergency medicine pharmacy, until now.  The EmpoweRx Conference, to be held in concurrently with the SAEM Annual Meeting, is designed by practicing emergency medicine pharmacists. The program will include a multidisciplinary and multispecialty […] The post Episode 95. “You're Breaking my Heart”: Acute Coronary Syndrome appeared first on The Pharm So Hard Podcast.

MONA is the acronym sometimes used to help us remember the interventions to consider for patients with Acute Coronary Syndrome.Morphine's use in the Acute Coronary Syndrome (ACS) algorithm.Why Morphine is helpful for patients with ACS.Contraindications and considerations for the safe administration of Morphine.Morphine as an alternative to nitro for patients with chest pain that take PDE inhibitors.Common dosing & administration of Morphine.Monitoring of the patient's level of consciousness, pain, blood pressure, and respirations after administration. Possible side effects of Morphine administration. Narcan as an antidote to Morphine if needed.Connect with me:Website: https://passacls.com@PassACLS on Twitter@Pass-ACLS-Podcast on LinkedInGive back & support the show:via PayPal Good luck with your ACLS class!

Looking for more information on this topic? Check out the Drugs to Treat Acute Coronary Syndrome brick. If you enjoyed this episode, we'd love for you to leave a review on Apple Podcasts.  It helps with our visibility, and the more med students (or future med students) listen to the podcast, the more we can provide to the future physicians of the world. Follow USMLE-Rx at: Facebook: www.facebook.com/usmlerx Blog: www.firstaidteam.com Twitter: https://twitter.com/firstaidteam Twitter: https://twitter.com/mesage_hub Instagram: https://www.instagram.com/firstaidteam/ YouTube: www.youtube.com/USMLERX Learn more about Rx Bricks by signing up for a free USMLE-Rx account: www.usmle-rx.com You will get 5 days of full access to our Rx360+ program, including over 800 Rx Bricks.  After the 5-day period, you will still be able to access over 150 free bricks, including the entire collections for General Microbiology and Cellular and Molecular Biology.